CN Patent

CN112368024A — 治疗癌症的方法

Assigned to Endocyte Inc · Expires 2021-02-12 · 5y expired

What this patent protects

本文中描述的本发明涉及用于靶向疗法的药物递送缀合物。本文中描述的本发明涉及用式1化合物治疗表达PSMA的癌症的方法。本文中描述的本发明还涉及用式1化合物治疗患者的表达PSMA的癌症的方法，其中疾病在用所述式1化合物治疗之后得到稳定。

USPTO Abstract

本文中描述的本发明涉及用于靶向疗法的药物递送缀合物。本文中描述的本发明涉及用式1化合物治疗表达PSMA的癌症的方法。本文中描述的本发明还涉及用式1化合物治疗患者的表达PSMA的癌症的方法，其中疾病在用所述式1化合物治疗之后得到稳定。

Drugs covered by this patent

Patent Metadata

Patent number
CN112368024A
Jurisdiction
CN
Classification
—
Expires
2021-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Endocyte Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.